Online inquiry

IVTScrip™ mRNA-Anti-ITGAV&ITGB3, MEDI-522(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11311MR)

This product GTTS-WQ11311MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets ITGAV&ITGB3 gene. The antibody can be applied in Sarcoma research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001144999.3; NM_000212.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3685; 3690
UniProt ID P06756; P05106
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ITGAV&ITGB3, MEDI-522(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ11311MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5379MR IVTScrip™ mRNA-Anti-env, CD4(178) PE40(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CD4(178) PE40
GTTS-WQ11143MR IVTScrip™ mRNA-Anti-IFNA1, MDX-1103(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MDX-1103
GTTS-WQ13808MR IVTScrip™ mRNA-Anti-S, REGN-10933(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA REGN-10933
GTTS-WQ853MR IVTScrip™ mRNA-Anti-PRLR, ABBV-176(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ABBV-176
GTTS-WQ9244MR IVTScrip™ mRNA-Anti-MUC1, IMMU-107(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA IMMU-107
GTTS-WQ10371MR IVTScrip™ mRNA-Anti-APP, LY2062430(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA LY2062430
GTTS-WQ11813MR IVTScrip™ mRNA-Anti-PDCD1, MK-3475(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MK-3475
GTTS-WQ14688MR IVTScrip™ mRNA-Anti-MS4A1, SCT-400(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA SCT-400
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW